Comprehensive Analysis of Ferroptosis- and Immune-Related Signatures to Improve the Prognosis and Diagnosis of Kidney Renal Clear Cell Carcinoma

Frontiers in Immunology

Jiheng Liu¹  Tong Duan¹  Yan Zhou¹  Qi Zuo¹  Yan Liu²  Huirong Zhang²  Zhiquan Xiao²  Ping Bu²  Huanfa Zhou²  Xiao-Liang Xing³ 

[1] Department of Emergency, First Hospital of Changsha, Changsha, China;Department of General Medicine, University of South China affiliated Changsha Central Hospital, Changsha, China;School of Public Health and Laboratory Medicine, Hunan University of Medicine, Huaihua, China;

关键词: KIRC;    methylation;    ferroptosis;    immune;    prognosis;    diagnosis;   

DOI  :  10.3389/fimmu.2022.851312

来源: DOAJ

【 摘 要 】

BackgroundAlmost 40% of patients with kidney renal clear cell carcinoma (KIRC) with advanced cancers eventually develop to metastases, and their 5-year survival rates are approximately 10%. Aberrant DNA methylations are significantly associated with the development of KIRC. The aim of our present study was to identify suitable ferroptosis- and immune-related (FI) biomarkers correlated with aberrant methylations to improve the prognosis and diagnosis of KIRC.MethodsChAMP and DESeq2 in R (3.6.2) were used to screen the differentially expressed methylation probes and differentially expressed genes, respectively. Univariate and multivariate Cox regression were used to identify the overall survival (OS)–related biomarkers.ResultsWe finally identified five FI biomarkers (CCR4, CMTM3, IFITM1, MX2, and NR3C2) that were independently correlated with the OS of KIRC. The area under the curve value of the receiver operating characteristic value of prognosis model was 0.74, 0.68, and 0.72 in the training, validation, and entire cohorts, respectively. The sensitivity and specificity of the diagnosis model were 0.8698 and 0.9722, respectively. In addition, the prognosis model was also significantly correlated with several immune cells and factors.ConclusionOur present study suggested that these five FI-DEGs (CCR4, CMTM3, IFITM1, MX2, and NR3C2) could be used as prognosis and diagnosis biomarkers for patients with KIRC, but further cross-validation clinical studies are still needed to confirm them.

【 授权许可】

Unknown